The 15th World Conference on Lung Cancer is drawing to a close in Sydney, Australia. By all accounts it’s been a successful meeting with several thousand delegates from all over the world.
We were not able to make it to Sydney, so have been following the meeting remotely. For us the Fall conference circuit this year has been ECCO in Amsterdam, AACR-NCI-EORTC Molecular Targets in Boston and we’ll next be at annual meeting of the American Society of Hematology in New Orleans.
At World Lung, AstraZeneca and Clovis Oncology presented new clinical data for their anti-EGF compounds against the T790M mutation in patients refractory to at least one prior EGFR therapy. This is a hot topic and potential good news for patients given their are no effective therapies on the market that target this mutation.
At the recent ECCO meeting in Amsterdam, AstraZeneca came out of left field to stun the audience with some exciting late-breaking data on AZD9291. By the time we reached Molecular Targets in Boston, they had ramped up the phase 1 trial from 1 site in Manchester to 28 around the world!
In Sydney, Malcolm Ranson from the Christie Hospital provided an update today on progress with AZD9291, while Jean-Charles Soria (Gustave Roussy) presented the Clovis CO-1686 data on Monday, including early results from the new formulation.
You can read more on Biotech Strategy Blog about what is one of the most promising drugs in the AstraZeneca pipeline.